Orexo AB (FRA:C5G)
€ 0.885 0.004 (0.45%) Market Cap: 31.52 Mil Enterprise Value: 73.01 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Q2 2021 Orexo AB Earnings Call Transcript

Jul 15, 2021 / 01:00PM GMT
Release Date Price: €3.81 (-1.70%)
Operator

Hello, and welcome to the Orexo AB Q2 report of 2021. (Operator Instructions)

Today, I'm pleased to present Nikolaj Sørensen, Chief Executive Officer. Please begin your meeting.

Nikolaj SÃ;rensen;publ;President;CEO
Orexo AB

¸ - ()-&

Thank you very much, and again, welcome to the first half results for Orexo. It's no doubt today has been a sweaty day not only due to the heat wave in Sweden, but also with looking at our share price. However, when I'm looking into our [Q] report and looking at the progress we have made on both ZUBSOLV and also on our digital therapies, I think there are some quite strong reasons to be optimistic about the development moving forward.

And with that, I will start the presentation, and I will go into Page #4. So Page 4. A short summary of the quarter here. So if we look at the U.S. Pharma business, we have seen a stable sales comparing to the last quarter. The positive part is that our core segment, the open market, in particular, the open commercial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot